DS101 shows early positive results in rosacea

BOSTON — DS101 cream improved redness and severity of facial rosacea, according to a poster presented at the American Academy of Dermatology Annual Meeting.

“DS101 (DS Biopharma) is a novel bioactive lipid cream containing a unique combination of the imega-3 fatty acid eicosapentaenoic acid (EPA) and the omega-6 fatty acid gamma-linolenic acid (GLA),” Moayed Hamza, MD, of DS Biopharma in Dublin, Ireland, and colleagues wrote. “DS10’s active ingredients are anti-inflammatory, anti-oxidative and photo-protective against ultraviolet radiation.”

This single center, open-label trial evaluated twice-daily topical DS101 in 20 patients with rosacea.

At week 12, Investigator Global Assessment scores were reduced by a mean of 57% compared with baseline and erythema was reduced by a mean 41%. Skin water content increased 34% in the same time period.

Additionally, redness, dryness, skin tone evenness, visual smoothness, tactile softness, clarity and radiance were also significantly improved.

No adverse events were reported.

“Twice-daily DS101 cream was well-tolerated and provided significant improvements in investigator and subject-assessed outcomes in patients with mild to moderate rosacea and sensitive skin,” the authors wrote.